Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
The therapeutic benefits of immune checkpoint inhibitors (ICIs), which enable antitumor immune responses, can be tempered by unwanted immune-related adverse events (irAEs). Treatment recommendations stratified by irAE phenotype and immunohistopathological findings have only recently been proposed an...
Saved in:
| Main Authors: | , , |
|---|---|
| 格式: | Revisão |
| 語言: | 英语 |
| 出版: |
2022
|
| 在線閱讀: | https://doi.org/10.1136/jitc-2021-003551 https://jitc.bmj.com/content/jitc/10/1/e003551.full.pdf |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|